Arcus Biosciences (RCUS)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Immuno-Oncologysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 50/100 (MEDIUM), 4.9 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 14.72% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Arcus Biosciences Announces New Employment Inducement Grants
- Is Arcus Biosciences (RCUS) Undervalued As New Casdatifan Data Takes Center Stage?
- Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy
- Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)’s Cancer Drug Partnership Create a New Treatment Standard?
- Arcus Biosciences (RCUS) Q2 2026 Earnings Call Transcript
- Arcus Biosciences' Casdatifan Therapy Could be Launched in 2028, Morgan Stanley Says
- Arcus Biosciences Q2 Earnings Call Highlights
- Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Arcus Biosciences.
Full RCUS Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.